Autologous T cells engineered to express a chimeric antigen receptor (often targeting CD19) to recognize and kill malignant B cells.
Autologous T cells are genetically engineered to express a chimeric antigen receptor (often targeting CD19) that recognizes tumor antigens independent of MHC, activating the T cells to proliferate and kill antigen-positive malignant B cells via cytotoxic mechanisms (perforin/granzyme) and cytokine release.
CAR-engineered T cells recognize CD19 on target cells and kill them via T-cell cytotoxicity—primarily perforin/granzyme-mediated apoptosis, with contributions from death-receptor signaling and cytokines.
An antibody–drug conjugate targeting CLDN18.2 that delivers the microtubule inhibitor monomethyl auristatin E (MMAE, vedotin) to induce direct cytotoxicity, bystander killing, and Fc-mediated ADCC.
CLDN18.2-targeted monoclonal antibody linked via a cleavable linker to the microtubule inhibitor MMAE (vedotin). After binding CLDN18.2 and internalization, MMAE is released to inhibit tubulin polymerization, causing G2/M arrest and apoptosis; also enables bystander killing and Fc-mediated ADCC.
ADC binds CLDN18.2, is internalized, and releases MMAE (vedotin) that inhibits microtubule polymerization, causing G2/M arrest and apoptosis; Fc can also mediate ADCC and the payload enables bystander killing.
Humanized IgG1 monoclonal antibody against CD20 that depletes circulating CD20+ B cells via complement- and Fc-mediated cytotoxicity, reducing B-cell antigen presentation and proinflammatory cytokines.
Humanized IgG1 monoclonal antibody targeting CD20 on B cells; depletes circulating CD20+ B cells via complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, reducing B-cell antigen presentation and proinflammatory cytokine production.
Binds CD20 on B cells and induces complement-dependent cytotoxicity (CDC) and Fc-mediated effector killing (ADCC/ADCP), leading to lysis and depletion of CD20+ cells.
Fully human IgG1 monoclonal antibody targeting CD20 that induces potent complement-mediated depletion of CD20+ B cells.
Fully human IgG1 monoclonal antibody targeting CD20 on B cells; induces complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, depleting CD20+ B cells and dampening B cell–mediated immune activity.
Anti-CD20 IgG1 binds CD20 on B cells and induces complement-dependent cytotoxicity and Fcγ receptor–mediated ADCC, leading to lysis of CD20+ cells.
Humanized monoclonal antibody against HER2/ERBB2; binds the extracellular domain of HER2 to inhibit receptor signaling and proliferation, and recruits immune effector functions to mediate antibody‑dependent cell‑mediated cytotoxicity (ADCC) against HER2‑overexpressing tumor cells.
Binds HER2 on tumor cells and engages FcγR+ immune effectors (e.g., NK cells) to induce antibody‑dependent cellular cytotoxicity; may also trigger complement‑dependent cytotoxicity.